In Brief: Boston Life Sciences
This article was originally published in The Gray Sheet
Boston Life Sciences: Initial studies of the firm's Altropane imaging agent for rapid single photon emission computerized tomography (SPECT) scan diagnosis of Parkinson's disease show the agent "allows for accurate diagnosis of Parkinson's disease in less than two hours after injection," the firm states in a June 5 release. Studies of 15 subjects, including seven healthy patients and eight Parkinson's patients, were presented at the annual Society of Nuclear Medicine meeting in San Antonio, Texas during the week of June 2. The studies "demonstrated that Altropane accumulated rapidly and selectively in the dopamine transporters" of healthy patient brains and that accumulation "was markedly reduced" in Parkinson's patients, the firm says...
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.